What Aminoverse does

Aminoverse B.V. is a Netherlands-based biotech contract research organization (CRO) founded in January 2020 and headquartered in Nuth near the tri-border of the Netherlands, Belgium, and Germany. The company specializes in enzyme research and development, providing services spanning enzyme discovery, profiling, engineering, library generation, and custom production to pharmaceutical, biotech, flavors & fragrances, and chemical industry customers. Its commercial model is hybrid: fee-for-service CRO engagements, often delivered under shared-risk or royalty-free terms, alongside direct sale of proprietary enzyme panels (UPO, KGO, Human CYP, Lipase) and the Phosfinity polyphosphate analysis kits from mg to kg scale.

The technical backbone combines wet lab capabilities — a 200 sqm ML-1/GMO-certified lab, three microbial production platforms (E. coli, B. subtilis, P. pastoris), and 100+ enzyme assays — with three proprietary AI platforms: EnzyMAP AI (mutation fitness landscape prediction, claimed to reduce screening burden by 80%), EnzyREC AI (recombinatorial mutation prediction), and EnzyNAV AI (sequence mining across more than 2 billion enzyme candidates). The September 2025 strategic collaboration with UK-based Prozomix extended access to 6,000+ native biocatalysts, and the company holds freedom-to-operate IP on its flagship 77-enzyme UPO panel, the world's largest unspecific peroxygenase collection. Named customers span enterprise pharma (Sandoz), biotech startups (Primopus, Zya, Photanol), and academic institutions (Bielefeld University, MIT, Harvard Medical School).

Aminoverse operates as a privately held, founder-owned, bootstrapped company with no disclosed institutional or venture capital investment, emphasizing sustainable organic growth from a team of approximately 22 named scientists, business developers, and operational staff led by founder and CEO David Schönauer. Revenue is generated globally through direct inquiry-driven sales, with international product shipping from the Netherlands and an expanding footprint of industry conferences, webinars, and thought-leadership content under the brand promise of "Enzyme Research meets AI."

Name

Aminoverse

Legal name

Aminoverse B.V.

Website

https://aminoverse.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Aminoverse is a Netherlands-based biotech CRO that combines proprietary AI platforms with wet lab expertise to deliver enzyme discovery, engineering, profiling, and production services plus proprietary enzyme panels and the Phosfinity polyphosphate kit line to pharma, biotech, flavors & fragrances, and academic customers globally.

Ownership category

akta.pro rank

Product category

Biotech Contract Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Food Manufacturing (311)

SIC

Miscellaneous Food Preparations & Kindred Products (2090), Services-Prepackaged Software (7372)

akta.pro primary industry

Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF)

akta.pro secondary industries

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Protein Processing Enzymes (Meat/Seafood/Plant) (AFAJAIAF), Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)

Keywords

• Enzyme research development
• Biocatalysis services
• Contract research organization
• AI enzyme engineering
• Biotech CRO

Headquarters

HQ city

Nuth

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Enzyme R&D Services: Contract research services including enzyme discovery, profiling, engineering, library generation, and custom production. Services are delivered as fee-for-service with shared-risk models and are royalty-free.
2. Enzyme Products: Sale of enzyme panels (UPO, KGO, Lipase, Human CYP) and Phosfinity kits for polyphosphate analysis. Products available in ready-to-screen formats from mg to kg scale.
3. Enzyme Production: Custom enzyme production from µg to g scale, with scaling support to kg scale through CDMO network partners. Three microbial production platforms: E. coli, B. subtilis, and P. pastoris.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Aminoverse is a biotech CRO that delivers enzyme research and development services spanning discovery, profiling, engineering, library generation, and custom production. The company sells proprietary enzyme panels (UPO, KGO, Lipase, Human CYP) and Phosfinity polyphosphate kits directly, and applies its proprietary AI platforms (EnzyMAP, EnzyREC, EnzyNAV) to accelerate enzyme engineering projects with reduced screening requirements.

Product overview

Aminoverse is a biotech CRO offering a comprehensive enzyme R&D portfolio combining AI-powered platforms with wet lab services. The core product line includes enzyme panels: the UPO Enzyme Panel (77 unspecific peroxygenases, the world's largest), four KGO Enzyme Panels (AminoAcid, BioCarbon, XNA, Eureka totaling over 150 curated Fe(II)-α-ketoglutarate-dependent oxygenases), Human CYP Enzyme Panel (8 isoforms), Lipase Enzyme Panels (both free and immobilized forms), and Phosfinity kits for polyphosphate analysis. The AI platform consists of EnzyMAP (mutation fitness landscape prediction), EnzyREC (recombination AI), and EnzyNAV (sequence discovery from billions of candidates). Services span the full innovation chain: Enzyme Discovery, Enzyme Engineering, Enzyme Profiling, Enzyme Libraries, and Enzyme Production. Products are available from mg to kg scale with freedom-to-operate IP.

Differentiator

Problem solved

Functional benefit

Brands

• EnzyMAP AI: AI platform for discovering up to 100% of all point mutations that improve enzyme performance, requiring 80% less screening capacity
• EnzyREC AI
• EnzyNAV AI
• Phosfinity

Products and services

• UPO Enzyme Panel Largest collection of 77 unspecific peroxygenases (UPOs) worldwide for oxyfunctionalization of APIs and intermediates, free of third-party IP. Supports reactions including hydroxylation, demethylation, epoxidation, and sulfoxidation. Available from mg to kg scale for pharmaceutical and chemical companies.
• AminoAcid KGO Enzyme Panel 46 curated Fe(II)-α-ketoglutarate-dependent oxygenases for regio- and stereoselective oxyfunctionalization of canonical and non-canonical amino acids. Supports pharmaceutical and peptide engineering applications.
• BioCarbon KGO Enzyme Panel 28 curated KGOs for hydroxylation of fatty acids, terpenes, alkaloids, and steroids. Targets flavors, fragrances, agrochemicals, and hormone modification.
• XNA KGO Enzyme Panel 22 curated Fe(II)-α-ketoglutarate-dependent oxygenases for site-selective modification of nucleosides, nucleotides, DNA, RNA, and derivatives. Supports RNA therapeutics and oligonucleotide applications.
• Eureka KGO Enzyme Panel 41 KGO enzymes mined from sequence space with in silico prediction, structural modeling, and patent landscaping. Broad applications including antibiotic development and modification of complex substrates.
• Human CYP Enzyme Panel 8 major human cytochrome P450 isoforms (CYP1A1, CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2E1, CYP2D6, CYP3A4) recombinantly expressed in Pichia pastoris for drug metabolism screening and DDI assessments.
• Lipase Enzyme Panel (Non-immobilized) 9 free lipases including BTL2, CALA, CALB, CTL, RML, ROL, TLL variants for hydrolysis, esterification, transesterification, and aminolysis reactions.
• Immobilized Lipase Kit 7 immobilized lipases including BTL2, CALB variant, CRL3, CRL4, CTL, RML, TLL for enhanced stability, organic solvent tolerance, and continuous-flow systems. Developed with Bisy and ChiralVision.
• Phosfinity Quant Enzyme-based kit for rapid quantification of total polyphosphate content in research samples (blood, soil, water, plants, microorganisms). Processes 100 samples in parallel with colorimetric endpoint detection.
• Phosfinity ChainQuant World's first kit for measuring polyphosphate chain lengths. Determines average total polyphosphate chain length and concentration. Co-developed with RWTH Aachen.
• Enzyme Discovery Service Discovery of freedom-to-operate enzymes using bioinformatics, metagenomics, structural biology, and EnzyNAV AI. Includes custom enzyme panel generation and worldwide shipment for pharmaceutical, biotech, and chemical companies.
• Enzyme Engineering Service AI-powered enzyme evolution using EnzyMAP and EnzyREC AI platforms. Identifies all hotspots, assesses evolvability, and recombines top mutations for superior enzyme performance. Delivered as fee-for-service with shared-risk and royalty-free IP models.
• Enzyme Profiling Service Enzyme performance characterization with 100+ assays for pharmacokinetics, quality control, and high-throughput library screening. Includes assay development and kinetic profiling for pharma, biotech, and academic customers.
• Enzyme Libraries Service Generation of holistic enzyme libraries (full site saturation mutagenesis) with >95% correctness verified by NGS. Also includes combinatorial enzyme libraries without length restrictions, scar-free cloning, and NGS verification.
• Enzyme Production Service Custom enzyme production from microgram to gram scale using E. coli, B. subtilis, or P. pastoris microbial hosts. Includes fermentation and downstream processing up to 15L bioreactor with scaling support to kg scale through CDMO network partners.

Quantifiable outcome

• 80% less screening capacity and budget required using EnzyMAP AI
• +5 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Partnerships

Four partnerships are on record, tiered core.

• ProzomixcoreStrategic or Co-development Partner · 10 September 2025Strategic collaboration announced September 10, 2025. Aminoverse gains access to Prozomix's complete portfolio spanning >6000 diverse native biocatalysts for use in its R&D service projects. Enables integration of vast biocatalytic diversity into screening and engineering workflows. Prozomix benefits from broadened market access through Aminoverse's global client network. Collaboration bridges enzyme diversity with enzyme innovation.
• Bisy GmbHcoreStrategic or Co-development PartnerLong-standing development partner for enzyme products including Human CYP enzyme panel and immobilized lipase kit. Bisy provides enzyme science expertise and supply up to kg scale. Joint development ensures cutting-edge enzyme products.
• ChiralVisioncoreStrategic or Co-development PartnerEnzyme Technology Alliance member for immobilized lipase kit development. Ensures industrially relevant performance and scalability of enzyme products.
• RWTH Aachen University (Prof. Dr. Lars M. Blank, Dr. Jonas J. Christ)coreTechnology or IntegrationCo-development of Phosfinity Quant and ChainQuant kits. Prof. Dr. Blank is Head of Institute of Applied Microbiology, and Dr. Christ is former PostDoc at the same institute. Both are experts in polyphosphate analytics.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Enzymicals: European CRO focused on enzyme process development, custom production, and biocatalysis services for pharma and chemical industries. Comparable in service-only enzyme CRO model, microbial production platforms, and customer overlap in pharma process chemistry.
• Codexis: US-listed enzyme engineering company developing engineered enzymes for pharmaceutical and sustainable chemistry applications. Most direct comparable in enzyme engineering CRO/services plus proprietary biocatalyst products serving pharma and F&F customers.
• ChiralVision: Dutch immobilized enzyme and biocatalysis company developing lipase and other immobilised enzyme kits. Highly comparable in producing IP-clean, immobilised enzyme panels for industrial biocatalysis and a current partner in Aminoverse's Enzyme Technology Alliance.
• c-LEcta: German enzyme engineering company offering contract development and proprietary enzyme products for pharmaceutical, food, and industrial biotech applications. Comparable in offering curated enzyme panels, custom engineering services, and IP-clean biocatalysts.
• Arzeda: AI-driven protein design company combining computational design with wet-lab validation to engineer novel enzymes. Highly comparable in marrying proprietary AI (similar positioning to EnzyMAP/EnzyREC/EnzyNAV) with fee-for-service and licensing revenue.
• Prozomix: UK-based enzyme diversity provider offering one of the largest curated biocatalyst libraries (>6,000 enzymes) to academic and industrial users. Direct comparable as a supplier of off-the-shelf enzyme panels and discovery libraries; also an active strategic partner.
• Bisy GmbH: Austrian enzyme product company producing recombinant enzymes including P450 CYPs and lipases, co-developing products with Aminoverse. Comparable in supplying curated, IP-clean enzyme panels to academic and industrial customers at mg-to-kg scale.

Emerging players

• Creative Enzymes: US-based supplier of enzyme products and custom enzyme services to academic and industrial buyers. Comparable as an emerging catalog-and-service enzyme provider with overlapping customer base in academic and industrial research.

Broad incumbents

• Ginkgo Bioworks: Large US synthetic biology platform offering end-to-end organism and enzyme engineering services across pharma, agriculture, and industrial biotech. Overlaps in protein/enzyme engineering and AI-driven strain design, but serves a much broader portfolio at significantly greater scale.

Regional players

• Synaffix: Netherlands-based biotech platform company licensing proprietary payload, linker, and conjugation technology. Comparable as a specialised, capital-efficient Dutch biotech CRO/licensing business of similar size that monetises proprietary technology assets globally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/aminoverse

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aminoverse